{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:29:37Z","timestamp":1787002177534,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T00:00:00Z","timestamp":1360627200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/bjc.2013.59","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T16:45:34Z","timestamp":1360687534000},"page":"1021-1026","source":"Crossref","is-referenced-by-count":112,"title":["Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial"],"prefix":"10.1038","volume":"108","author":[{"given":"N","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D S","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P E","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Braly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Morosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P F","family":"Dodion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,12]]},"reference":[{"key":"BFbjc201359_CR1","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/cncr.24431","volume":"115","author":"VL Bae-Jump","year":"2009","unstructured":"Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA (2009) Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 115: 3887\u20133896","journal-title":"Cancer"},{"key":"BFbjc201359_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ygyno.2010.08.025","volume":"119","author":"VL Bae-Jump","year":"2010","unstructured":"Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA (2010) Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol 119: 579\u2013585","journal-title":"Gynecol Oncol"},{"key":"BFbjc201359_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","volume":"30","author":"SP Chawla","year":"2012","unstructured":"Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D\u2019Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 30: 78\u201384","journal-title":"J Clin Oncol"},{"key":"BFbjc201359_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejogrb.2010.07.038","volume":"153","author":"CH Choi","year":"2010","unstructured":"Choi CH, Lee JS, Kim SR, Kim TJ, Lee JW, Kim BG, Bae DS (2010) Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 153: 207\u2013210","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"BFbjc201359_CR5","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/0008-5472.CAN-08-1274","volume":"68","author":"T Daikoku","year":"2008","unstructured":"Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, Ellenson LH, Dey SK (2008) Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68: 5619\u20135627","journal-title":"Cancer Res"},{"key":"BFbjc201359_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209\u2013219","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc201359_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/fon.11.57","volume":"7","author":"JE Dancey","year":"2011","unstructured":"Dancey JE, Monzon J (2011) Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Fut Oncol 7: 827\u2013839","journal-title":"Fut Oncol"},{"key":"BFbjc201359_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrclinonc.2010.216","volume":"8","author":"KJ Dedes","year":"2011","unstructured":"Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261\u2013271","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc201359_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1586\/era.09.54","volume":"9","author":"TH Dellinger","year":"2009","unstructured":"Dellinger TH, Monk BJ (2009) Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther 9: 905\u2013916","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFbjc201359_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ygyno.2010.02.007","volume":"117","author":"DS Dizon","year":"2010","unstructured":"Dizon DS (2010) Treatment options for advanced endometrial carcinoma. Gynecol Oncol 117: 373\u2013381","journal-title":"Gynecol Oncol"},{"key":"BFbjc201359_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247","journal-title":"Eur J Cancer"},{"key":"BFbjc201359_CR12","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1200\/JCO.2007.10.8431","volume":"25","author":"GF Fleming","year":"2007","unstructured":"Fleming GF (2007) Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 25: 2983\u20132990","journal-title":"J Clin Oncol"},{"key":"BFbjc201359_CR13","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1158\/1078-0432.CCR-06-1375","volume":"12","author":"MP Hayes","year":"2006","unstructured":"Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932\u20135935","journal-title":"Clin Cancer Res"},{"key":"BFbjc201359_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","volume":"10","author":"F Janku","year":"2011","unstructured":"Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol Cancer Ther 10: 558\u2013565","journal-title":"Mol Cancer Ther"},{"key":"BFbjc201359_CR15","doi-asserted-by":"publisher","first-page":"17298","DOI":"10.1073\/pnas.1012548107","volume":"107","author":"S Memarzadeh","year":"2010","unstructured":"Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, Schafenacker AM, Huang J, Witte ON (2010) Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci USA 107: 17298\u201317303","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc201359_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","volume":"26","author":"MM Mita","year":"2008","unstructured":"Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26: 361\u2013367","journal-title":"J Clin Oncol"},{"key":"BFbjc201359_CR17","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","volume":"29","author":"AM Oza","year":"2011","unstructured":"Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA (2011a) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278\u20133285","journal-title":"J Clin Oncol"},{"key":"BFbjc201359_CR18","volume-title":"Presented at the 47th Annual Meeting of the American Society of Clinical Oncology","author":"AM Oza","year":"2011","unstructured":"Oza AM, Poveda A, Del Campo JM, Richard A, Dorer DJ, Haluska F (2011b) A randomized phase II trial of ridaforolimus compared with progestin or chemotheraphy in female adult patients with advanced endometrial carcinoma. Presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 3\u20137 June"},{"key":"BFbjc201359_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2006.10.007","volume":"33","author":"D Pectasides","year":"2007","unstructured":"Pectasides D, Pectasides E, Economopoulos T (2007) Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33: 177\u2013190","journal-title":"Cancer Treat Rev"},{"key":"BFbjc201359_CR20","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","volume":"15","author":"AP Pilotte","year":"2011","unstructured":"Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N (2011) Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 15: E83\u2013E89","journal-title":"Clin J Oncol Nurs"},{"key":"BFbjc201359_CR21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","volume":"14","author":"DA Rizzieri","year":"2008","unstructured":"Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14: 2756\u20132762","journal-title":"Clin Cancer Res"},{"key":"BFbjc201359_CR22","first-page":"1615","volume":"25","author":"HB Salvesen","year":"2004","unstructured":"Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S (2004) Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25: 1615\u20131623","journal-title":"Int J Oncol"},{"key":"BFbjc201359_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00280-011-1788-4","volume":"69","author":"Y Seki","year":"2012","unstructured":"Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T (2012) Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 69: 1099\u20131105","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc201359_CR24","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/ijc.24837","volume":"126","author":"A Shafer","year":"2010","unstructured":"Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL (2010) Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 126: 1144\u20131154","journal-title":"Int J Cancer"},{"key":"BFbjc201359_CR25","doi-asserted-by":"publisher","first-page":"e16209","DOI":"10.1371\/journal.pone.0016209","volume":"6","author":"BY Shorning","year":"2011","unstructured":"Shorning BY, Griffiths D, Clarke AR (2011) Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 6: e16209","journal-title":"PLoS One"},{"key":"BFbjc201359_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212\u2013236","journal-title":"CA Cancer J Clin"},{"key":"BFbjc201359_CR27","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1002\/cncr.25515","volume":"116","author":"BM Slomovitz","year":"2010","unstructured":"Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116: 5415\u20135419","journal-title":"Cancer"},{"key":"BFbjc201359_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/AOG.0b013e318162f690","volume":"111","author":"JI Sorosky","year":"2008","unstructured":"Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111: 436\u2013447","journal-title":"Obstet Gynecol"},{"key":"BFbjc201359_CR29","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-11-0273","volume":"10","author":"RM Squillace","year":"2011","unstructured":"Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, Wang F, Clackson T, Rivera VM (2011) Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 10: 1959\u20131968","journal-title":"Mol Cancer Ther"},{"key":"BFbjc201359_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2010.02.022","volume":"117","author":"SM Temkin","year":"2010","unstructured":"Temkin SM, Yamada SD, Fleming GF (2010) A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and\/or recurrent gynaecologic malignancies. Gynecol Oncol 117: 473\u2013476","journal-title":"Gynecol Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201359","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T17:25:57Z","timestamp":1714929957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFbjc201359"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.59","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,12]]}}}